Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers

被引：2
|
作者：
McCusker, Elizabeth A. [1 ,2 ]
Loy, Clement T. [3 ]
机构：
[1] Westmead Hosp, Sydney, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, Australia
[3] Macquarie Univ, Macquarie Med Sch, Sydney, Australia
来源：
NEUROLOGY | 2023年 / 100卷 / 21期
关键词：
SOCIETY;
D O I：
10.1212/WNL.0000000000207199
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
With the advent of promising, biomarker-directed, amyloid monoclonal antibody therapy for Alzheimer disease (AD),(1) there is a need to understand the complex scientific, ethical, and practical implications related to biomarkers of neurodegenerative conditions,(2) including how they can be used to determine the onset, progression, and subtype of these disorders. As the clinical use of AD biomarkers moves beyond specialized centers, and as they become widely used to identify, diagnose, and track the progression of dementia, it will be important to develop protocols to disclose the presence of AD biomarkers to patients.
引用
收藏
页码：993 / 994
页数：2
相关论文
共 50 条
12345